Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. α1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. A Prospective, Randomized, Controlled, Multicenter Study of Naftopidil for Treatment of Male Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: 75 mg Once Daily in the Evening Compared to 25 mg Thrice Daily [Comparison of naftopidil and silodosin in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, crossover study]. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Effect of naftopidil on nocturia after failure of tamsulosin. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Randomized Controlled Trial to Assess the Efficacy of the Combination Therapy of Alfuzosin and Tadalafil in Patients with Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Comparing efficacy of α1D-receptor antagonist naftopidil and α1A/D-receptor antagonist tamsulosin in management of distal ureteral stones Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia
BACKGROUND The present study investigated the efficacy , safety , and utility of starting an alpha(1d)-selective antagonist , naftopidil , at 75 or 25 mg/day in patients with lower urinary tract symptoms ( LUTS ) associated with benign prostatic hyperplasia ( BPH ) . METHODS In this prospect i ve comparative study , the subjects comprised 153 patients with LUTS associated with BPH . Patients were r and omized to receive either 25 mg/day ( Group LD ) or 75 mg/day ( Group HD ) of naftopidil for 4 weeks . The lower urinary tract disease symptom score ( LUTDSS ) , the International Prostate Symptom Score ( IPSS ) , the Quality of life assessment index , the maximum flow rate ( Q(max ) ) , and the residual urine volume were compared between the groups . RESULTS In both groups , the LUTDSS and the IPSS were significantly improved at the endpoint and no significant intergroup differences were identified . However , the improvement in the Q(max ) was significantly better for Group HD than for Group LD . The overall efficacy did not differ significantly between the groups . The degree of improvement in voiding symptoms and LUTDSS among patients with moderate symptoms was significantly greater for Group HD than for Group LD . The frequency of adverse reactions did not differ significantly between the groups . CONCLUSIONS Starting administration at 75 mg/day rather than 25mg/day is helpful for LUTS associated with BPH for patients with moderate symptoms , particularly in improving voiding symptoms . The 75 mg/day administration was considered to be a recommendable therapeutic dose in some patients OBJECTIVES To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil .  METHODS A total of 95 patients received 50 mg/day of naftopidil for 8 weeks . After this treatment period , they were divided into two groups : the poor responders were defined as those who either had an International Prostate Symptom Score- Quality of Life ≥ 4 or with an International Prostate Symptom Score- Quality of Life of 3 whose International Prostate Symptom Score- Quality of Life improved < 2 points ( group A ) . All other patients were defined as responders to naftopidil 50 mg/day ( group B ) . The dose of naftopidil was increased to 75 mg/day in group A , and maintained at 50 mg/day in group B. The treatment was continued for a further 8 weeks . RESULTS The prostate volume at the baseline was significantly larger in group A than group B. The improvement of International Prostate Symptom Score total score , International Prostate Symptom Score- Quality of Life , and voided volume after 8 weeks was significantly better in group B than in group A. However , there was no significant difference in the changes of all parameters between the two groups after 16 weeks . CONCLUSIONS A dose increase to 75 mg/day is an effective treatment strategy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to an initial dose of 50 mg/day of naftopidil . Furthermore , a starting dose of 75 mg/day should be considered in patients with a large prostate volume , as this is a predictive factor for dose increase Objectives . To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms ( LUTSs ) . Methods . Based on the IPSS , men reporting LUTS were prospect ively studied using 50 mg/day of naftopidil for the first 4 weeks ; satisfied patients continued its 50 mg/day ( n = 11 ) , and those reporting unsatisfactory improvement received its 75 mg/day ( n = 35 ) for the next 4 weeks . Results . The 75 mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner ( at 4 weeks : P < .001 , at 4 weeks versus 8 weeks : P < .05 ) . In the 50 mg group , both scores reduced at 4 weeks , thereafter unchanged . The baseline slow stream score alone was higher in the 75 mg group ( P = .013 ) . The rate of change in the QOL score during the initial 4 weeks ( ΔQOL ) and Δnocturia was smaller in the 75 mg group ( P < .05 ) . Conclusions . Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil Naftopidil , approved only in Japan , is an α1-adrenergic receptor antagonist ( α1-blocker ) used to treat lower urinary tract symptoms ( LUTS ) suggestive of benign prostatic hyperplasia ( BPH ) . Different from tamsulosin hydrochloride and silodosin , in that it has higher and extremely higher affinity respectively , for the α1A-adrenergic receptor subtype than for the α1D type , naftopidil has distinct characteristics because it has a three times greater affinity for the α1D-adrenergic receptor subtype than for the α1A subtype . Although well- design ed large-scale r and omized controlled studies are lacking and the optimal dosage of naftopidil is not always completely determined , previous reports from Japan have shown that naftopidil has superior efficacy to a placebo and comparable efficacy to other α1-blockers such as tamsulosin . On the other h and , the incidences of ejaculatory disorders and intraoperative floppy iris syndrome induced by naftopidil may be lower than for tamsulosin and silodosin having high affinity for the α1A-adrenergic receptor subtype . However , it remains unknown if the efficacy and safety of naftopidil in Japanese is applicable to white , black and Hispanic men having LUTS/BPH in western countries There is no consensus on the evaluated efficacy of individual alpha(1)-blockers in the treatment of lower urinary tract symptoms ( LUTS ) associated with benign prostatic hyperplasia ( BPH ) . This study compared the clinical benefits of tamsulosin hydrochloride with those of naftopidil in BPH . Men aged 54 - 84 years with a main complaint of BPH were r and omly assigned to receive consecutive treatment with tamsulosin then naftopidil ( T-N group , 25 patients ) , or naftopidil then tamsulosin hydrochloride ( N-T group , 20 patients ) . The therapeutic effects were compared in a crossover design . Administration was continued for 28 days in each treatment period . Both groups showed similar improvements during the first treatment period . However , during the second treatment period after crossover , therapeutic effects were greater in the N-T group . Tamsulosin was more effective than naftopidil on intermittency , nocturia and quality of life scores .  Tamsulosin and naftopidil have different efficacy profiles for LUTS associated with BPH OBJECTIVES To investigate the benefit of alpha1-adrenoceptor antagonist naftopidil on the quality of life ( QOL ) of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia ( BPH/LUTS ) . METHODS A total of 99 men with BPH/LUTS were prospect ively recruited . The Short Form-8 ( SF-8 ) was used for generic QOL assessment and each parameter was compared with the norm in these patients . Longitudinal changes were evaluated using the SF-8 and the International Prostatic Symptoms Score ( I-PSS ) at baseline , 4 and 8 weeks after naftopidil administration . The relationship between SF-8 and I-PSS was analyzed . RESULTS Five of eight components in the SF-8 were significantly lower than the Japanese national norm at baseline . SF-8 score was improved by naftopidil at 4 and 8 weeks in general health ( GH ) and physical component summary ( PCS ) in the patients in their 70s . Mental health ( MH ) and mental component summary ( MCS ) were improved at 8 weeks in patients in their 60s . When analyzing the whole cohort , SF-8 GH , role emotional ( RE ) and MH had improved at 8 weeks , which was similar to the norm , and bodily pain ( BP ) results were better . Compared with the baseline , total I-PSS , storage/voiding symptoms and QOL index scores improved significantly under naftopidil . Each component of I-PSS ( except for hesitancy ) correlated with SF-8 sub-scales ( except for BP ) to some extent . CONCLUSIONS BPH/LUTS impairs generic QOL , which is improved by naftopidil treatment . SF-8 can be a useful instrument to assess the efficacy of BPH/LUTS treatment because its simplicity to complete and analyze , and its meaningful relationship to I-PSS OBJECTIVES To examine the effect of alpha 1D/A adrenoceptor inhibitor naftopidil on health-related quality of life ( QOL ) in men with benign prostatic hyperplasia ( BPH ) . METHODS A total of 56 newly diagnosed patients with symptomatic BPH were prospect ively enrolled and treated with 50 mg naftopidil daily for more than 12 weeks . All underwent pre-treatment documentation of lower urinary tract symptoms , QOL assessment using the international prostate symptom score ( IPSS ) and King 's Health Question naire ( KHQ ) , and uroflowmetry . A post-treatment assessment was performed at 12 weeks . RESULTS IPSS scores as well as QOL index showed a significant improvement after naftopidil administration . Similarly , all seven domains except general health perceptions and social limitations in the KHQ question naire were significantly improved . When dividing the patients into overactive bladder ( OAB ) and non-OAB groups , only the OAB group showed significant improvement in almost all the domains of KHQ . Change ratios of the IPSS were not associated with those of KHQ domain scores in the OAB group . On the other h and , in the non-OAB group more domains presented improvements , which were associated with those of IPSS scores . CONCLUSIONS Twelve-week treatment with naftopidil for symptomatic BPH patients is associated with significant improvement in the IPSS , QOL index , maximum urinary flow rate , post-void residual urine volume ( PVR ) and almost all domains in KHQ . KHQ is useful for the evaluation of clinical response in BPH patients , particularly in those with associated OAB Introduction : We examined the tolerability of dosage methods of naftopidil in the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia ( BPH/male LUTS ) . Patients and Methods : A total of 80 patients with BPH/male LUTS who had an International Prostate Symptom Score ( IPSS ) ≧8 and IPSS quality of life ( QoL ) ≧2 were enrolled and r and omly administered naftopidil for 8 weeks at either 75 mg once daily ( OD ) in the evening ( group O ; n = 41 ) or 25 mg thrice daily ( TID ) in the morning , afternoon and evening ( group T ; n = 39 ) . Results : IPSS total score , IPSS-QoL and BPH impact index ( BII ) were significantly improved for both groups at 8 weeks after starting treatment compared to baseline . IPSS total score and daytime and 24-hour voiding frequencies were significantly improved at 8 weeks after starting treatment for group O in comparison to group T. Group O showed a significantly better degree of change in BII in comparison to group T. Conclusions : Naftopidil 75 mg OD in the evening was better tolerated than naftopidil 25 mg TID for the objective parameter and BII We compared the efficacy , safety , and patient preferences for two α1-adrenoceptor ( AR ) antagonists with different affinity for AR subtypes , naftopidil ( Naf ) and silodosin ( Silo ) , for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia ( male LUTS/BPH ) . New patients diagnosed with male LUTS/BPH were r and omly divided into either the Naf-Silo group or the Silo-Naf group ( Naf : 50 - 75 mg once daily for 2 weeks followed by 75 mg once daily for 4 weeks ; Silo : 2 - 4 mg twice daily for 2 weeks followed by 4 mg twice daily for 4 weeks ) . A survey was conducted to evaluate patient drug preferences after completion of the study and the reasons for the preferences . Naf and Silo  improved the total International Prostate Symptom Score ( IPSS ) compared with baseline . There was no significant difference between Naf and Silo in improvement in the IPSS total score . Adverse effects were more frequent with Silo than with Naf ( P=0 . 002 ) . No significant difference in patient preference for the drugs was observed . These findings indicate that Naf and Silo provide similar clinical efficacy , with no difference in patient preference for the drugs , although adverse effects were significantly more frequent with Silo than with Naf OBJECTIVE To compare the efficacy and safety of a fixed dose ( 0.2 mg ) of tamsulosin , a selective alpha 1A-adrenoreceptor antagonist , with an increasing dose ( 1 - 5 mg ) of terazosin , a non-selective antagonist , in the treatment of urinary outflow obstruction associated with benign prostatic hyperplasia ( BPH ) in Korean patients . PATIENTS AND METHODS The study comprised a single-blind and r and omized design with tamsulosin or terazosin taken once daily for 8 weeks . A total of 98 patients was enrolled , with 72 patients included in the analyses after 4 and 8 weeks . The primary variables assessed were changes in the maximum urinary flow rate Qmax and the total International Prostate Symptom Score ( IPSS ) , with the post-void residual urine volume , ' obstructive ' and ' irritative ' questions in the IPSS , and the investigators ' global assessment of efficacy also determined . The number of patients with a clinical ly significant response to treatment with tamsulosin or terazosin was determined and defined as those with > 20 % improvement from the baseline Qmax or > 20 % decrease in total IPSS . Adverse reactions possibly or probably related to study medication were recorded throughout the treatment period . RESULTS Both tamsulosin and terazosin produced similar significant improvements in subjective and objective symptoms of urinary outflow obstruction ( P > 0.05 ) . Systolic and diastolic ( st and ing ) blood pressures decreased significantly in patients treated with terazosin ( P < 0.05 ) . The adverse reactions , most frequently dry mouth and dizziness which were usually mild and transient , were significantly higher in patients on terazosin ( 18 patients , versus one on tamsulosin , P < 0.001 ) . The changes led to discontinuation of therapy in two patients on terazosin . CONCLUSION Tamsulosin was as effective as terazosin in treating urinary outflow obstruction associated with BPH , but had a markedly better safety profile OBJECTIVES The clinical usefulness of naftopidil was evaluated in 122 patients with benign prostatic hyperplasia for urinary tract symptoms and signs , focused in particular on nocturia . METHODS A total of 122 patients with BPH whose symptoms did not improve after 6 weeks of tamsulosin administration were enrolled . After the treatment was followed by a washout period with placebo , patients were prescribed 75 mg of naftopidil to be taken after dinner for 6 weeks , and the efficacy was re-evaluated . All the drugs used were unidentified , and attention was given to not have the patients recognize the change in the drug given . The primary purpose of this study was the improvement of nocturia in patients with a poor response to tamsulosin . The clinical efficacy of naftopidil was defined as significant improvement in International Prostate Symptom Score , quality -of-life index , and maximal urinary flow rate . RESULTS After 6 weeks of naftopidil administration , significant improvements in daytime and nighttime frequency , International Prostate Symptom Score , quality -of-life index , maximal flow rate , average flow rate , and bladder compliance were examined . On the International Prostate Symptom Score question naire , improvement in the sensation of the bladder not emptying and a reduction in nighttime frequency stood out . Moreover , detrusor overactivity was observed in 40 patients before the start of treatment and was eliminated in 31 . The effective rate of this study was 69.7 % ( 85/122 ) . CONCLUSIONS Naftopidil has novel effects in patients with BPH whose main complaints are storage and voiding symptoms , especially that of nocturia of > or=3 times , as well as in patients with a low compliance bladder and detrusor overactivity , who did not respond to tamsulosin OBJECTIVES In order to compare the clinical efficacy of naftopidil ( Naf ) and tamsulosin hydrochloride ( Tam ) , which differ in their selectivity to alpha receptor subtypes , we performed a multi-center prospect i ve r and omized controlled study . METHODS Men complaining of lower urinary tract symptoms due to benign prostatic hypertrophy , were r and omized into two treatment groups : one receiving 50 mg Naftopidil daily ( Naf group , n = 31 pts ) , and one receiving 0.2 mg Tam once daily ( Tam  group , n = 28 pts ) . Baseline symptom scores were compared to those at 2 weeks and at the end of the observation period ( 6 - 8 weeks ) . RESULTS In the Naf group at 2 weeks , the score of the daytime frequency significantly improved from 3.5 to 2.2 ( P = 0.03 ) , and the score of nocturia improved significantly from 3.5 to 2.2 ( P = 0.0004 ) , respectively . In the Tam group at 2 weeks , however , no significant improvement was noted in the increased score of daytime frequency ( P = 0.1 ) or nocturia ( P = 0.2 ) . At 2 weeks , the storage symptom score of the frequency to the combined score of daytime frequencies and the score of nocturia was better in the Naf group ( improved from 7.0 to 4.4 , P = 0.0017 ) than in the Tam group ( from 6.8 to 4.9 , P = 0.08 ) ( P < 0.05 ) . At 6 - 8 weeks , the effects of the two drugs on lower urinary tract symptoms were comparable . CONCLUSIONS Naf demonstrated a significant early response to improve storage symptoms at 2 weeks , including daytime frequency and nocturia , compared with Tam AIM The aim of our study was to examine the efficacy of naftopidil in terms of the international prostate symptom score ( IPSS ) and urodynamic parameters in the treatment of benign prostatic hyperplasia ( BPH ) . Eviprostat was used as a control to study the efficacy of naftopidil . METHODS Forty-nine patients with BPH ( mean age 67.9 + /- 7.8 years ) were involved in the study . Patients were r and omly assigned either to the naftopidil group , which was treated with the alpha-blocker naftopidil ( 50 - 75 mg daily , 36 patients ) , or the eviprostat group , which was treated with phytotherapy ( six tablets of eviprostat daily , 13 patients ) . RESULTS The mean total IPSS , the total storage and voiding symptom scores , and the quality of life score decreased significantly ( P < 0.0001 for each variable ) in the naftopidil group , but not in the eviprostat group . In the naftopidil group , analyses showed significant increases in average and maximum flow rate and bladder capacity at first desire to void ( P < 0.001 , P = 0.001 and P = 0.024 , respectively ) , and significant decreases in the postvoid residual , the percent of residual and the Abrams-Griffiths number ( P = 0.009 , P = 0.008 and P = 0.042 , respectively ) . However , in the eviprostat group , no significant changes were noted in terms of these symptomatic and urodynamic parameters . In the pressure/flow study , an improvement in the International Continence Society nomogram grade was noted in 29 % of the naftopidil group , but in only 16 % of the eviprostat group . Among the 14 patients in the naftopidil group , detrusor overactivity disappeared in 21 % and cystometric capacity increased in 36 % , but no improvement in detrusor overactivity was noted in the eviprostat group . CONCLUSIONS Naftopidil appears to have been effective in this short-term treatment of BPH BACKGROUND The aim of the study presented here was to stratify drug therapy for patients with benign prostatic hyperplasia ( BPH ) displaying various voiding symptoms . METHODS Two different alpha1-adrenoceptor antagonists ; tamsulosin hydrochloride ( Tam ) and naftopidil ( Naf ) , were administered to 96 patients with BPH for 8 weeks in a crossover study . RESULTS With the administration of both drugs , the International Prostate Symptom Score ( I-PSS ) significantly decreased and the maximum urinary flow significantly increased . Whereas Naf monotherapy decreased the I-PSS for storage symptoms , Tam monotherapy decreased the I-PSS for voiding symptoms . In both the Naf-to-Tam and Tam-to-Naf groups , crossover was effective when the initial drug was judged subjectively and objective ly to have been ineffective . Compliance was acceptable with both drugs . CONCLUSION Our results show that either Naf or Tam can be used to treat patients on the basis of objective and subjective assessment of voiding symptoms . Our findings should be helpful for patient guidance and treatment of BPH OBJECTIVE The purpose of our study was to evaluate the effect of alfuzosin and tadalafil as combination therapy compared with each monotherapy , in patients with lower urinary tract symptoms ( LUTS ) due to benign prostatic hyperplasia ( BPH ) . METHODS Men over the age of 50 years with LUTS secondary to BPH and an International Prostate Symptom Score ( IPSS ) 8 or higher , were r and omized to receive 10 mg alfuzosin ( n = 25 ) , 10 mg tadalafil ( n = 25 ) or the combination of both the drugs ( n = 25 ) once daily for 3 months . Symptoms were assessed at baseline , 6 weeks and 3 months . The primary endpoint was the change in IPSS from the baseline . Secondary endpoints were changes in IPSS storage and voiding subscores , peak urinary flow rate , residual urine volume , IPSS quality of life score and erectile domain score . RESULTS There were significant improvements in all IPSS scores , peak urinary flow rate and IPSS quality of life score from baseline at both 6 weeks and 3 months in all the three groups ( P < 0.003 ) . Combination therapy was better than monotherapy in improving IPSS scores and reducing post-void residual urine volume ( P < 0.005 ) . Combination therapy was similar to alfuzosin regarding improvement in maximum urine flow rate ( P = 0.22 ) , similar to tadalafil in improvement on erectile function ( P = 0.22 ) and better than each monotherapy in improving the IPSS quality of life ( P ≤ 0.015 ) . CONCLUSION Alfuzosin and tadalafil combination therapy provides greater symptomatic improvement as compared to either monotherapy in men with LUTS due to BPH Purpose To compare the efficacy of α1D-receptor antagonist Naftopidil and α1A/D-receptor antagonist Tamsulosin in management of  distal ureteral stones . Material s and methods A total of 131 patients with distal ureteral stones were included in the study from December 2008 to September 2010 . The patients were r and omized to 3 groups : group 1 ( 43 patients ) , those receiving 10 mg naftopidil once daily ; group 2 ( 45 patients ) , those receiving 0.4 mg tamsulosin once daily ; and group 3 ( 43 patients ) were given a watchful waiting and served as control group . All patients were followed up for 2 weeks . Ultrasonography and kidney-ureters-bladder ( KUB ) were performed on day 7 and 14 . At the end of the follow-up period , patients who failed to expel the stone were scheduled to undergo ESWL or ureteroscopy . Results Stone expulsion was observed in 31 patients in group 1 ( 72.1 % ) , 37 patients in group 2 ( 82.2 % ) , and 13 patients in group 3 ( 30.2 % ) . A statistically significant difference was noted with Chi-square testing between groups 1 and 3 , and groups 2 and 3 ( P = 0.000 and P = 0.000 , respectively ) . Average time to expulsion was 7.6 ± 2.26 days ( range 1–12 days ) in group 1 , 7.7 ± 1.94 days ( range 2–11 days ) in group 2 , and 9.4 ± 2.48 days ( range 6–14 days ) in group 3 . A statistically significant difference was observed in time to expulsion between groups 1 and 3 , and groups 2 and 3 ( P = 0.000 , P = 0.001 , respectively ) by ANOVA testing . The side effects encountered in the study groups were generally mild and did not require cessation of therapy in any patient . Conclusions Naftopidil could significantly increase spontaneous passage of distal ureteral stones with low side effects . The stone expulsion rate is similar for the tamsulosin Purpose The efficacy of a loading dose of α1-adrenoreceptor antagonist for patients with benign prostate hyperplasia who did not improve at a low dose has not been determined . We performed a prospect i ve study to estimate the efficacy of incremental naftopidil administration . Methods The efficacy of naftopidil was examined based on changes in the International Prostate Symptom Score ( IPSS ) . We defined a “ responder ” as a patient who improved by ≥5 points in IPSS total score . All patients were administered naftopidil at 50 mg/day for 12 weeks , and nonresponders at 50 mg/day were increased to 75 mg/day . Efficacy was finally evaluated after an additional 12 weeks of administration at 75 mg/day . Results Among 122 patients whose data could be analyzed , the efficacy rate after administration at 50 mg/day was 52.5 % . In all IPSS items except urgency score , the responders had significantly higher ( poorer ) values than nonresponders before the start of treatment . Of 40 patients whose dose was increased to 75 mg/day and whose data could be analyzed  , prostate volume in the responder group ( 9 patients ) was significantly smaller than that in the nonresponder group ( 31 patients ) . Multivariate analysis showed that patients with improved IPSS total score , voiding symptoms , urgency , and weak stream after administration of 50 mg/day naftopidil were more likely to improve after a dose increase . Conclusions A dose increment of naftopidil to 75 mg/day may be useful in patients with BPH who did not improve at 50 mg/day
Although additional well design ed , worldwide , placebo-controlled and r and omized studies are necessary to confirm the long-term outcomes of naftopidil pharmacotherapy , current data suggest that naftopidil administration in BPH patients provides comparable improvements in total IPSS , QoL , and urinary symptoms from baseline relative to 0.2 mg/d tamsulosin and 8 mg/d silodosin .
However , improvements in Qmax are generally less with naftopidil than with tamsulosin .
Reported adverse effects related to naftopidil administration are negligible and usually mild .
OBJECTIVES The aim of the study was to systematic ally review the effects of the adrenoreceptor A1D antagonist naftopidil in the management of  lower urinary tract symptoms ( LUTS ) .